Sponsor: Merck
Sponsor Study ID: MK 2870-019
Study Title: Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab W/WO MK2870 in Resectable Stages II-IIIB(N2) NSCLC for Patients not Achieving pCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy Followed by Surgery
CTO #: 103982
NCT Number:
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To compare MK-2870 plus pembrolizumab versus pembrolizumab monotherapy with respect to DFS as assessed by BICR. To compare MK-2870 plus pembrolizumab to pembrolizumab monotherapy with respect to OS.